Filing Details
- Accession Number:
- 0001209191-20-030498
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-19 16:35:24
- Reporting Period:
- 2020-05-15
- Accepted Time:
- 2020-05-19 16:35:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1735944 | Reshma Kewalramani | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-05-15 | 2 | $274.37 | 26,723 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 6 | $276.40 | 26,717 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 7 | $279.70 | 26,710 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 9 | $280.47 | 26,701 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 6 | $281.74 | 26,695 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 4 | $282.74 | 26,691 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 10 | $283.76 | 26,681 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 27 | $286.07 | 26,654 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 19 | $287.63 | 26,635 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 9 | $288.37 | 26,626 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $274.37 (range $274.03 to $274.71).
- Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $276.40 (range $275.85 to $276.75).
- Open market sales reported on this line occurred at a weighted average price of $279.70 (range $279.13 to $280.06).
- Open market sales reported on this line occurred at a weighted average price of $280.47 (range $280.16 to $280.73).
- Open market sales reported on this line occurred at a weighted average price of $281.74 (range $281.24 to $282.23).
- Open market sales reported on this line occurred at a weighted average price of $282.74 (range $282.46 to $283.35).
- Open market sales reported on this line occurred at a weighted average price of $286.07 (range $285.72 to $286.63).
- Open market sales reported on this line occurred at a weighted average price of $287.63 (range $287.18 to $288.10).
- Open market sales reported on this line occurred at a weighted average price of $288.37 (range $288.23 to $288.47).
Billionaire Hedge Funds
